Status:
UNKNOWN
Development of a Serocorrelate of Protection Against Invasive Group B Streptococcus Disease
Lead Sponsor:
St George's, University of London
Collaborating Sponsors:
Medical Research Council
University of Nottingham
Conditions:
Streptococcus Agalactiae Infection
Eligibility:
All Genders
Brief Summary
A multicentre study to provide evidence that the relationship between an immune marker value (anti-GBS IgG concentration) and the probability of invasive GBS (iGBS) disease in infants less than 90 day...
Detailed Description
Group B Streptococcus (GBS) is a bacterium (a bug) that causes serious infections in young infants across the world. In 2015 it was estimated that there were at least 319,000 infants under 3 months of...
Eligibility Criteria
Inclusion
- \-
Exclusion
- For iGBS disease case recruitment, an infant is not eligible unless a parent/person with parental responsibility gives informed consent For iGBS disease control recruitment, a mother is not eligible unless she gives informed consent.
Key Trial Info
Start Date :
December 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 30 2024
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04735419
Start Date
December 1 2021
End Date
March 30 2024
Last Update
November 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St George's University of London
London, United Kingdom, SW17 ORE